In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Infection susceptibility, poor vaccination efficacy, age-related disease onset, and neoplasms
are linked to innate and adaptive immune dysfunction that accompanies aging (known as …

All living things experience an increase in entropy, manifested as a loss of genetic and
epigenetic information. In yeast, epigenetic information is lost over time due to the …

Dementia in Alzheimer's disease progresses alongside neurodegeneration,,–, but the
specific events that cause neuronal dysfunction and death remain poorly understood. During …

Epigenetic clocks comprise a set of CpG sites whose DNA methylation levels measure
subject age. These clocks are acknowledged as a highly accurate molecular correlate of …

Tau aggregation in neurofibrillary tangles (NFTs) is closely associated with
neurodegeneration and cognitive decline in Alzheimer's disease (AD). However, the …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

The loss of vital cells within healthy tissues contributes to the development, progression and
treatment outcomes of many human disorders, including neurological and infectious …

Parkinson's disease is characterized by loss of dopamine neurons in the substantia nigra.
Similar to other major neurodegenerative disorders, there are no disease-modifying …

Protein aggregation is the hallmark of neurodegeneration, but the molecular mechanisms
underlying late-onset Alzheimer's disease (AD) are unclear. Here we integrated …